Building a leading microbiome company in oncology

We are addressing large and fast-growing markets with severe unmet medical needs.

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is completed.

Supporting the development and expansion of its pipeline, MaaT Pharma has built a powerful discovery and analysis platform, gutPrint®, to determine novel disease targets, evaluate drug candidates and identify biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations.

Key figures

3

funding rounds

37

Equity raised to date

9

Non dilutive fundings

Our investors

Seventure Partners

With over €691 million in assets under management as of the end of 2017, Seventure Partners is a leading European venture capital firm. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, especially FinTech and AssurTech, in France and Germany, and in the life sciences field across Europe and North America. In life sciences, the four areas of focus include Biotechnology and Pharmaceuticals, Connected health and Medtech, Industrial biotechnology, and finally: MICROBIOME, nutrition, foodtech and personalized medicine.

Investments can range from €500 thousand to €10 million per round, or up to €20 million per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more information Visit Seventure

BPI France

Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances.

Bpifrance also provides extrafinancial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export…).

For more information Visit BPI France

BIOCODEX

Biocodex is an independent family-owned pharmaceutical company, founded in Paris, France in 1953. The company initially concentrated on gastroenterology and specifically on the discovery of a promising probiotic substance, Saccharomyces boulardii (sold under the ULTRA-LEVURE brand in France). Biocodex has maintained partnerships with health sector professionals for 60 years, with the mission of developing intelligent solutions that respond to contemporary healthcare issues. Biocodex has become a multinational research and development, manufacturing and marketing company.
The company is currently active in over 100 countries, with subsidiaries in Belgium, Russia, Ukraine, Turkey, Morocco, Mexico and the United States and through partnerships with distributors. Today, Biocodex specializes at international level in the therapeutic domains of gastroenterology, neuropsychiatry and pain treatment.
For more information Visit Biocodex

Crédit Mutuel Innovation

Crédit Mutuel Innovation is the evergreen venture capital entity of Crédit Mutuel Equity (€3.5 billion in capital). We invest €1-20M in life science, digital and deeptech companies from seed to growth stages.
We help bold and ambitious entrepreneurs to develop their strong growth potential with our worldwide enterprise ecosystem (our 350+ portfolio companies, our abroad subsidiaries, 150+ largest global corporates and the best-in-class experts). Because it takes more than 5 years to build a Unicorn, we invest our own equity and ensure durable partnerships with visionary leaders. Today, the 350 companies in which we have invested generate a cumulative annual turnover of €50bn and create more than 250,000 jobs.
For more information Visit Crédit Mutuel Innovation

Celeste Management

Celeste Management is a single-family office based in Geneva primarily investing in alternative asset classes (Private Equity, Infrastructure, Venture, Real Estate, Private Debt), with a broad geographic spread and a long-term horizon.

Celeste Management supports ambitious growth projects in promising areas such as the development of renewable energies, reduction of the ecological footprint, education and training, health, the silver economy, nutrition and the transformation of consumer habits, telecom and internet networks, digitalization, mobility and logistics.

For more information Visit Celeste Management

Skyviews Life Science

For more information Visit Sky Views Life Science

Symbiosis

SymBiosis Capital Management, LLC is a venture capital firm focused on advancing biotherapeutics innovations.
For more information Visit Symbiosis

INRAE

The INRAE Transfert portfolio includes 420 active licenses of patents, know-how and software exploitation generating annual royalty turnover of over €4 million. INRAE Transfert manages 30 major European programs coordinated by INRAE. INRAE Transfert, the INRAE subsidiary, is a company focused on project engineering and the management of technology transfer to foster food, agricultural and environmental innovation. INRAE Transfert enhances and manages the INRAE technology portfolio through operating agreements with manufacturers and supports the development of innovative young companies.

As an intermediary between the research and business worlds, INRAE Transfert has five main missions:

Transferring research results to companies by promoting and managing INRAE’s portfolio of technologies, through operating agreements with the industrial sector.
Promoting the creation of innovative companies, by supporting their development.
Supporting the setup, negotiation and management of European or national collaborative research projects using their expertise in project engineering.
Setting up and managing large partnership research programs.
Providing resources to support innovation.

For more information Visit INRAE

Contact form